Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Orphazyme A/S stock | $4.02

Learn how to easily invest in Orphazyme A/S stock.

Orphazyme A/S
+ $0.15 ( + 3.73%)

Orphazyme A/S is a biotechnology business based in the US. Orphazyme A/S shares (ORPH) are listed on the NASDAQ and all prices are listed in US Dollars. Orphazyme A/S employs 180 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Orphazyme A/S

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ORPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Orphazyme A/S stock price (NASDAQ: ORPH)

Use our graph to track the performance of ORPH stocks over time.

Orphazyme A/S shares at a glance

Information last updated 2021-10-18.
Latest market close$4.02
52-week range$3.78 - $23.90
50-day moving average $4.51
200-day moving average $6.39
Wall St. target price$1.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.98

Buy Orphazyme A/S shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Orphazyme A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Orphazyme A/S price performance over time

Historical closes compared with the close of $4.02 from 2021-10-18

1 week (2021-10-13) -18.13%
1 month (2021-09-20) -7.37%
3 months (2021-07-20) -24.44%
6 months (2021-04-20) -54.42%
1 year (2020-10-20) -62.39%
2 years (2019-10-16) N/A
3 years (2018-10-16) N/A
5 years (2016-10-16) N/A

Orphazyme A/S financials

Revenue TTM $13.2 million
Gross profit TTM $0
Return on assets TTM -88.16%
Return on equity TTM -251.34%
Profit margin 0%
Book value $4.77
Market capitalisation $153.3 million

TTM: trailing 12 months

Shorting Orphazyme A/S shares

There are currently 302,519 Orphazyme A/S shares held short by investors – that's known as Orphazyme A/S's "short interest". This figure is 0.7% up from 300,548 last month.

There are a few different ways that this level of interest in shorting Orphazyme A/S shares can be evaluated.

Orphazyme A/S's "short interest ratio" (SIR)

Orphazyme A/S's "short interest ratio" (SIR) is the quantity of Orphazyme A/S shares currently shorted divided by the average quantity of Orphazyme A/S shares traded daily (recently around 1.1 million). Orphazyme A/S's SIR currently stands at 0.28. In other words for every 100,000 Orphazyme A/S shares traded daily on the market, roughly 280 shares are currently held short.

To gain some more context, you can compare Orphazyme A/S's short interest ratio against those of similar companies.

However Orphazyme A/S's short interest can also be evaluated against the total number of Orphazyme A/S shares, or, against the total number of tradable Orphazyme A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orphazyme A/S's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Orphazyme A/S shares in existence, roughly 10 shares are currently held short) or 0.0107% of the tradable shares (for every 100,000 tradable Orphazyme A/S shares, roughly 11 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Orphazyme A/S.

Find out more about how you can short Orphazyme A/S stock.

Orphazyme A/S share dividends

We're not expecting Orphazyme A/S to pay a dividend over the next 12 months.

Orphazyme A/S share price volatility

Over the last 12 months, Orphazyme A/S's shares have ranged in value from as little as $3.78 up to $23.9. A popular way to gauge a stock's volatility is its "beta".

ORPH.US volatility(beta: 0.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orphazyme A/S's is 0.7039. This would suggest that Orphazyme A/S's shares are less volatile than average (for this exchange).

To put Orphazyme A/S's beta into context you can compare it against those of similar companies.

Orphazyme A/S overview

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. .

Frequently asked questions

What percentage of Orphazyme A/S is owned by institutions?
Currently 2.251% of Orphazyme A/S shares are held by institutions.
How many people work for Orphazyme A/S?
Latest data suggests 180 work at Orphazyme A/S.
When does the fiscal year end for Orphazyme A/S?
Orphazyme A/S's fiscal year ends in December.
Where is Orphazyme A/S based?
Orphazyme A/S's address is: Ole MaalOees Vej 3, Copenhagen, Denmark, 2200
What is Orphazyme A/S's ISIN number?
Orphazyme A/S's international securities identification number is: US6873051022
What is Orphazyme A/S's CUSIP number?
Orphazyme A/S's Committee on Uniform Securities Identification Procedures number is: 687303107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site